

## Correction: Public-Health and Individual Approaches to Antiretroviral Therapy: Township South Africa and Switzerland Compared

Olivia Keiser, Catherine Orrell, Matthias Egger, Robin Wood, Martin W. G. Brinkhof, Hansjakob Furrer, Gilles van Cutsem, Bruno Ledergerber, Andrew Boulle, for the Swiss HIV Cohort Study (SHCS) and the International Epidemiologic Databases to Evaluate AIDS in Southern Africa (IeDEA-SA)

Correction for:

Keiser O, Orrell C, Egger M, Wood R, Brinkhof MWG, et al. (2008) Public-health and individual approaches to antiretroviral therapy: Township South Africa and Switzerland compared. *PLoS Med* 5(7): e148. doi:10.1371/journal.pmed.0050148

The Table 1 originally published with this manuscript stated that 95.1% of the patients from South Africa used regimens recommended by guidelines, compared to 99.6% in the Swiss cohort. This is incorrect: the figures have been reversed. As the article text makes clear, 95.1% of the Swiss patients used regimens recommended by guidelines, compared to 99.6% in the South African cohorts.

A corrected version of Table 1 is published here.

**Table 1.** Baseline Characteristics of Patients Starting HAART in Khayelitsha and Gugulethu, South Africa and the Swiss HIV Cohort Study

Category	Subcategory	South African Cohorts	Swiss HIV Cohort
Patients, <i>n</i>	—	2,348	1,016
	Females, <i>n</i> (%)	1,663 (71%)	333 (33%)
Age, <i>y</i> , median (IQR)	—	32.7 (28.5–38.2)	38.3 (31.7–46.1)
CD4 cell count, cells/ $\mu$ l, median (IQR)	—	80 (30–138)	204 (122–291)
CD4 cell count, number missing (%)	—	123 (5.2%)	50 (4.9%)
HIV-1 viral load, log <sub>10</sub> copies/ml, median (IQR)	—	5.1 (4.6–5.5)	5.0 (4.5–5.5)
HIV-1 viral load, number missing (%)	—	288 (12.3%)	53 (5.2%)
Clinical stage: CDC stage C, WHO stage III/IV, <i>n</i> (%)	—	2,126 (90.6%)	188 (18.5%)
Duration of follow-up (years) <sup>a</sup> , median (IQR)	—	0.9 (0.5–1.5)	2.0 (1.1–2.0)
Number of patients starting HAART in year, <i>n</i> (%)	2001	79 (3.4%)	179 (17.6%)
	2002	246 (10.5%)	204 (20.1%)
	2003	509 (21.7%)	185 (18.2%)
	2004–2006 <sup>b</sup>	1,514 (64.5%)	448 (44.1%)
	Initial HAART regimen, <i>n</i> (%)	2 NRTIs + 1 NNRTI	2,339 (99.7%)
	2 NRTIs + 1 PI	9 (0.4%)	449 (44.2%)
	Other	0	97 (9.6%)
Four most commonly used initial HAART regimens, <i>n</i> (%)	3TC D4T EFV	918 (39.1%)	—
	3TC D4T NVP	780 (33.2%)	—
	3TC AZT EFV	425 (18.1%)	—
	3TC AZT NVP	216 (9.2%)	—
	3TC AZT EFV	—	304 (29.9%)
	3TC AZT LPV/r	—	202 (19.9%)
	3TC AZT NFV	—	99 (9.7%)
	3TC TNV EFV	—	65 (6.4%)
Initial HAART regimens used to treat 95% of patients, <i>n</i>	—	4	36
Patients using initial HAART regimens recommended by guidelines, %	—	99.6	95.1

<sup>a</sup>Censored after 2 y.

<sup>b</sup>Recruitment not completed for the years 2005/06.  
doi:10.1371/journal.pmed.0050195.t001

Citation: Keiser O, Orrell C, Egger M, Wood R, Brinkhof MWG, et al. (2008) Correction: Public-Health and Individual Approaches to Antiretroviral Therapy: Township South Africa and Switzerland Compared. *PLoS Med* 5(9): e195. doi:10.1371/journal.pmed.0050195

Received: August 13, 2008; Accepted: August 13, 2008; Published: September 30, 2008.

Copyright: © 2008 Keiser et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.